AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on November 12, 2025, at 2:00 p.m. U.S. Pacific Standard Time (November 13, 2025, at 9:00 a.m. Australian Eastern Daylight Time). The webinar presentation will cover fi...
Ensurge Micropower ASA - Mandatory Notice of Trade for Primary Insiders Reference is made to the stock exchange announcement from Ensurge Micropower ASA ("Ensurge" or the "Company") today regarding a private placement of shares in the Company raising NOK 100 million at a subscription price of NOK 0.90 per share (the "Private Placement"). The following primary insiders (and closely associated companies) were allocated shares in the Private Placement: * AS Mascot Holding, close associate of Alexander Munch-Thore (Chairperson of the Board)* Coretech AS, close associate of Thomas Ramm (Board m...
Ensurge Micropower ASA - Key information relating to possible repair issue/subsequent offering Oslo, 9 November 2025 Reference is made to the stock exchange announcement from Ensurge Micropower ASA ("Ensurge" or the "Company") today regarding a private placement of shares in the Company raising NOK 100 million at a subscription price of NOK 0.90 per share (the "Private Placement") and a possible subsequent offering, raising up to NOK 20 million, at the same subscription price as in the private placement (the "Subsequent Offering"), subject to approval by an Extraordinary General Meeting t...
Ensurge Micropower ASA – Private Placement successfully placed NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, Norway, 9 November 2025 Reference is made to the stock exchange announcements published on 6 November 2025 and 7 November 2025 (the “Announcements”) by Ensurge Micropower ASA ("Ensu...
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies an...
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 51.6% to $24.8 million in the third quarter of 2025 from $16.4 million in the third quarter of 2024Total Company Adjusted EBITDA(1) was $84.9 million in the third quarter of 2025 as compared with $73.7 million in the...
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular events NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Associat...
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analyses today from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking p...
The report deals with the statistical and graph (non-technical) analysis of AKTOR GROUP stock. It includes analysis of stock returns, analysis of volume patterns and the stock’s beta coefficient. Moreover, the report provides information about AKTOR GROUP stock’s listing and participation in indices, and the stock’s shareholder structure.
Review of economic indicators and financial markets, forecasts on selective macroeconomic metrics - Inflation, Public Finances, Unemployment, Balance of Payments, Income from Tourism, Income from Shipping, Athens Exchange General Index, Market Risk, Industry Betas, P/E Multiples, Corporate Tax Rates, Bond Yields, Economic Sentiment Index, Business Confidence Index, Real Estate Prices, Sovereign Ratings, Interest Rates and Foreign Direct Investment.
Legrand SA, formerly Legrand SNC, is a France-based company. The Company predominantly specializes in electrical and digital building infrastructure. Its range of products are suitable for the commercial, industrial, and residential segments of the low voltage market. The Company has commercial and industrial operations in over 90 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.